ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

Silvio Danese  ¹     Brian G. Feagan  ^{2, 3, 3}     Fernando Magro  ^{4, 5}     Peter L Lakatos  ⁶     James O. Lindsay  ⁷     Tadakazu Hisamatsu  ⁸     Britta Siegmund  ^{9, 10}     Elena Dubcenco  ¹¹     Ana Paula Machado De Lacerda     Andrew Garrison     Chirag Doshi     James D. Lewis  ^12    
1 IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy
² Alimentiv, London, Canada
³ Western University, London, Canada
⁴ Centro Hospitalar São João, Porto, Portugal
⁵ University of Porto, Porto, Portugal
⁶ McGill University Health Centre, Montreal, Canada
⁷ Blizard Institute, Barts Health NHS Trust, London, United Kingdom
⁸ Kyorin University School of Medicine, Mitaka, Japan
⁹ Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
¹⁰ Campus Benjamin Franklin, Berlin, Germany
¹¹ AbbVie Inc., North Chicago, United States
¹² University of Pennsylvania, Philadelphia, United States

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)